187 related articles for article (PubMed ID: 26909599)
1. Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.
Gari HH; Gearheart CM; Fosmire S; DeGala GD; Fan Z; Torkko KC; Edgerton SM; Lucia MS; Ray R; Thor AD; Porter CC; Lambert JR
Oncotarget; 2016 Mar; 7(13):15757-71. PubMed ID: 26909599
[TBL] [Abstract][Full Text] [Related]
2. PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.
Gari HH; DeGala GD; Ray R; Lucia MS; Lambert JR
Cancer Lett; 2016 Oct; 380(2):505-512. PubMed ID: 27452906
[TBL] [Abstract][Full Text] [Related]
3. Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival.
den Hollander P; Rawls K; Tsimelzon A; Shepherd J; Mazumdar A; Hill J; Fuqua SA; Chang JC; Osborne CK; Hilsenbeck SG; Mills GB; Brown PH
Cancer Res; 2016 Apr; 76(7):1942-53. PubMed ID: 26921331
[TBL] [Abstract][Full Text] [Related]
4. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
5. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
[TBL] [Abstract][Full Text] [Related]
6. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
7. Identification of FOXE3 transcription factor as a potent oncogenic factor in triple-negative breast cancer.
Wang H; Yang T; Yuan Y; Sun X
Biochem Biophys Res Commun; 2020 Feb; 523(1):78-85. PubMed ID: 31831170
[TBL] [Abstract][Full Text] [Related]
8. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
9. 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
Peck B; Bland P; Mavrommati I; Muirhead G; Cottom H; Wai PT; Maguire SL; Barker HE; Morrison E; Kriplani D; Yu L; Gibson A; Falgari G; Brennan K; Farnie G; Buus R; Marlow R; Novo D; Knight E; Guppy N; Kolarevic D; Susnjar S; Milijic NM; Naidoo K; Gazinska P; Roxanis I; Pancholi S; Martin LA; Holgersen EM; Cheang MCU; Noor F; Postel-Vinay S; Quinn G; McDade S; Krasny L; Huang P; Daley F; Wallberg F; Choudhary JS; Haider S; Tutt AN; Natrajan R
Cancer Res; 2021 Feb; 81(4):847-859. PubMed ID: 33509944
[TBL] [Abstract][Full Text] [Related]
10. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
[TBL] [Abstract][Full Text] [Related]
11. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
12. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
[TBL] [Abstract][Full Text] [Related]
14. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
Bilir B; Kucuk O; Moreno CS
J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
[TBL] [Abstract][Full Text] [Related]
15. Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Huang O; Zhang W; Zhi Q; Xue X; Liu H; Shen D; Geng M; Xie Z; Jiang M
Exp Biol Med (Maywood); 2015 Apr; 240(4):426-37. PubMed ID: 25304315
[TBL] [Abstract][Full Text] [Related]
16. Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3.
Ünal TD; Hamurcu Z; Delibaşı N; Çınar V; Güler A; Gökçe S; Nurdinov N; Ozpolat B
Anticancer Agents Med Chem; 2021; 21(3):355-364. PubMed ID: 32767958
[TBL] [Abstract][Full Text] [Related]
17. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
18. PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells.
Liu H; Al-aidaroos AQ; Wang H; Guo K; Li J; Zhang HF; Zeng Q
BMC Cancer; 2013 Feb; 13():80. PubMed ID: 23418787
[TBL] [Abstract][Full Text] [Related]
19. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
20. Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression.
He J; McLaughlin RP; van der Beek L; Canisius S; Wessels L; Smid M; Martens JWM; Foekens JA; Zhang Y; van de Water B
Oncogene; 2020 May; 39(20):4118-4131. PubMed ID: 32235890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
